The one thing about high quality penny stocks is that they rarely ever run high and fast at the same time.Most are slow growth but strong investments to certain levels. As science progress anyone can see that stem cell technology is going to be a major contributor but many here may believe that is all CalbaTech does and thats not true. I posted the link above for anyone to check out just what they do.They are really deep into DNA and molecular research also.Lets clear one thing up now though,this stock will not make you rich over night or even in a week or two,this is not a penny flip play.The OS is tight and trading shares even tighter so don't expect it to be an easy flipper unless MOMO is behind it. BTW I just got back from Florida,left a day early just in case the hurricane causes any evacuation traffic jambs.I hope all down there remain safe and get out if they can,I have a bad feeling about the new tropical storm (ALPHA) that is parallel to Wilma and just on the other side of Cuba,if they connect it could be bad and it will be right over Florida according to the maps.
posted
I'm not doubting anything you post questsolver, and i'm not being negative, just being lazy and curious. Haven't done my DD on this so i wanted to ask you, looking at the 2 and 3 year chart this has not done anything, just wondering if there is any news or anything on this, and why you feel that this company is a good long term investment? TIA for any reply and answers to my questions. Posts: 84 | From: South Korea | Registered: Mar 2005
| IP: Logged |
posted
ecko...this is complete differant then it was 3 years ago and even using the chart it shows that CLBE should be trading back in the normal range over .20,the lasy 10-K pretty much gave great guidance.Heres just 2 parts.
1. "The company believes that it will report a net profit for 2005."
2. Regarding LifeStem's stem cell banking service: "It is not unreasonable to project potential revenues approaching $100 Million within 36 to 48 months with as few as 10,000 clients."
posted
Stockmover...I recommend you do whatever you feel comfortable with,as for bailing out...I don't consider the volume today as bailing at all,hell I bought more shares in 2 days last week then all of todays volume.As I have been saying though shares are held tight here with an extremely low OS to boot! I totally expect them to announce profitability before year end and that will get some major attention,especially from the penny stock watchers.I won't be surprised at all to see them apply for AMEX or even the NAS in the near future.Patience will be required here though,its going to be a gradual climber and not a fast buck that many want.
either way you must decide what you need to do and personally I will respect your decision whether its to sell and move on or hold until year end at least,its your money and there are some fast movers out here for a quick buck thats why I never tie all my money up just in case I need to play some flippers!
posted
for new eyes getting to know what CalbaTech is really about.
CalbaTech is pursuing a strategy of combining products and technologies, and the companies that provide them, into the following divisions: 1) Molecular Applications; 2) Research Reagents; and 3) Cellular Therapeutics. By pursuing such a strategy, each division should produce value added and increasing returns on shareholders' investment through cross marketing of products and geographic expansion, as well as to achieve product enhancement and efficiency.
Molecula Research Laboratories, LLC
Molecula Research Laboratories, LLC ("Molecula"), located in Sterling, Virginia, is dedicated to meeting the needs of research scientists in the pharmaceutical, biotech, medical and academic research sectors by providing cell and molecular biology reagents and associated consumables. Molecula, a wholly owned subsidiary of the Company, is actively expanding its product range in siRNA. This builds upon its well-established reputation as a designer, manufacturer and supplier of active antisense oligonucleotides.
Molecula is focused on gene function solutions using RNAi technology. Their proprietary computer algorithm - T.A.R.G.E.T.? (The Advanced RNAi Guidance Evaluation Technology) system and 10 years of gene silencing experience, allows Molecula to consistently deliver active RNA duplexes for specific target gene silencing.
Molecula also develops and sells numerous research reagents for cell transfection, DNA and RNA purification, protein expression, gene expression analysis and other innovative and fundamental products. Molecula also sells transfection reagents, a novel IPTG replacement for increased protein expression, neuropeptides and biochemicals. Please see www.molecula.com.
KD Medical, Inc
CTI's first acquisition within the research reagent market was Molecula. Molecula has excellent design and manufacturing capabilities and is seeking opportunities to market its products on a larger scale.
After acquiring Molecula, the next step was to establish a more competitive entity capable of comprehensively supplying the specialist media and reagent needs of cell and molecular biology researchers. The product ranges of KD and Molecula are highly complementary, with little overlap. One of KD's greatest strengths is in the supply of specialized media for culture of model research organisms such as bacteria, yeast, insects and mammalian cell lines. It also supplies products to approximately 300 National Institutes of Health ("NIH") laboratories, contracts invaluable for establishing new products in a favorable government setting. Its secondary products are related to molecular biology reagents. Conversely, Molecula's primary focus is in the design and supply of high value molecular biology reagents such as siRNA and DNA antisense oligonucleotides. It also has reagents such as IPTG that are complementary to customized media. A large proportion of such research depends upon culture of a model organism (bacteria, fruit fly, etc.), which is genetically manipulated by transfection of customized oligonucleotides (siRNA). Thus, an alliance of KD and Molecula will be well placed to provide a competitive single source for these culture media transfection reagents and specialized modifier molecules such as siRNA. Further, as explained above, KD's long standing and trusted position, as a major in-house supplier to NIH will greatly ease entry of Molecula's siRNA into that major market. Please see www.kdmedical.com.
THE CELLULAR THERAPIES DIVISION
Strategy
The Cellular Therapies Division was created to house CalbaTech's emerging interests in cellular applications, particularly those relating to the use of adult stem cells. The Company believes this is an emerging market in which there are major opportunities for new entrants to establish new standards through novel stem cell research techniques and business models. The Company is positioning itself through strategic alliances to identify and take advantage of such opportunities as they emerge from the interaction between fundamental research and an evolving regulatory environment.
To this end, CalbaTech has incorporated LifeStem, Inc., to take advantage of this rapidly expanding market. In addition to advancing its business model for stem cell banking and the provision of purified stem cells to researchers, CalbaTech has filed a patent application for intellectual property relating to the efficient and effective delivery of stem cells to diseased or dead areas of the heart. This device should allow for effective and efficient delivery of stem cells to heart tissue to promote regeneration post myocardial infarction (heart attack). CalbaTech is currently seeking collaborative partners for this innovative device
LifeStem, Inc.
The market for stem cell technology is currently $500 million, and has been estimated to grow to $30 billion by the year 2010 (Source DMD). This is projected due to the growth of new cellular therapeutics based on embryonic and adult stem cells, as well as clinical applications to compete with, or complement, existing drug based therapeutics. LifeStem's strategy is to leverage the CalbaTech infrastructure of companies to obtain a leadership position in the fast emerging stem cells arena and become the preferred provider of adult stem cells to the clinical researcher as part of a comprehensive package of stem cell based services. In time, it is anticipated that elements of LifeStem's services will become standard practice in mainstream clinical applications, thus opening a much larger market to LifeStem as a cellular logistics services company.
LifeStem is positioning itself to become a leading supplier of "Cellular Logistics" in this large new market. The company is focused on the following: (1) Providing a stem cell banking service to affluent individuals; (2) Providing services and technologies to facilitate the efficient acquisition and delivery of purified adult stem cells to the research market; (3) Developing delivery devices for clinical applications; and (4) Developing clinical applications of specific stem cell based therapies.
Stem Cell Banking
The opportunity to collect and preserve healthy adult stem cells on a pre-disease basis is certain to revolutionize the practice of medicine. The power and promise of stem cell therapies is just beginning to be known but the development of new clinical applications and therapies is imminent.
posted
I put in multiple buys above the bid but just under the ask and they are not showing up yet,the bid should be showing .044 now or .043 at least.
posted
I just contacted the company and waiting a response now over something I know they have in the works and just want to know when they plan on a PR concerning some issues.
posted
Quest, I'm still holding, but wow, it's getting tough! I hope you get some solid information from them soon. I want to buy more, but I need to see a solid PR before I put more $$ into it.
-------------------- "As long as there are dreamers, there are dreams that will come true." Posts: 862 | From: CT Yankee..... in FLA | Registered: Aug 2005
| IP: Logged |
The Pentagon announced today the formation of a new 500-man elite fighting unit called the U. S. REDNECK SPECIAL FORCES (USRSF).
These 500 Kentucky, West Virginia, Mississippi, Louisiana, Missouri, Arkansas, Alabama, Georgia, Texas, Tennessee and North & South Carolina boys will be dropped into Iraq and have been given only the following five facts about terrorists:
1. The season opened today. 2. There ain't no limit. 3. Tastes like chicken. 4. They don't like beer, pickups, country music, or Jesus. 5. They are responsible for the death of Dale Earnhardt.
The mess in Iraq is expected to be over in about a week.
-------------------- "As long as there are dreamers, there are dreams that will come true." Posts: 862 | From: CT Yankee..... in FLA | Registered: Aug 2005
| IP: Logged |
posted
I don't see any news yet and I believe the 10-Q is due by mid November...that filing I can't wait to see! Following up from the 10-k they should show a profit or damn near and also projections in the $100 million area over the next 36/48 months for one division involving stem cells.
posted
WASHINGTON (MarketWatch) - The Senate won't act until early next year on legislation to loosen restrictions on federally funded research on embryonic stem cells, a top senator announced Friday.
In an announcement on the Senate floor, Sen. Arlen Specter, R-Pa., said that Senate Majority Leader Bill Frist, R-Tenn., "has committed to bringing it up as one of the first items next year," the Associated Press reported.
The deal eliminates a potential roadblock for a key spending bill. Specter had previously threatened to attach the legislation to the appropriations bill funding the departments of Labor and Health and Human Services - a move that was expected to delay action on the underlying legislation.
The agreement also releases Frist from a pledge to bring the stem-cell legislation to the floor this year. In July, Frist broke with President Bush and conservative Republicans by calling for an increase in federal funding.
The administration has placed strict limits on the use of federal money to fund research involving embryonic stem cells. The White House has said Bush would likely veto legislation that loosens those limits.
Frist's endorsement puts him at odds with anti-abortion advocates within his own party, who contend that embryonic stem-cell research destroys potential human life.
Advocates of expanded funding contend that the administration's restrictions have slowed the development of treatments for a range of diseases, including Alzheimer's disease, Parkinson's disease and diabetes.
The House has already passed similar legislation and backers believe they have the votes needed to achieve passage in the Senate.
posted
yeah but it looks like they needed to hit the .03's,it won't stay here long imo.Anywhere in this range is a great entry even for a short term double or triple within a few weeks.November will be good for this one and AMEP as I have stated before.
posted
They lowered the spread to 37x38 and I swooped in from another 50k....averaging down, usually the cardinal sin, but not if you believe in the longer term prospects.
-------------------- I may be wrong, but I don't think so.... Posts: 837 | From: Madison, WI | Registered: Sep 2005
| IP: Logged |
posted
I see that ARCA is usually the one that wants to crash the party. Might as well be ORCA, the giant killer whale, who gobbles up all the shares and doesn't play fair. Will sit and wait for the next blockbuster news to send this back north of .06
-------------------- I may be wrong, but I don't think so.... Posts: 837 | From: Madison, WI | Registered: Sep 2005
| IP: Logged |
posted
ARCA with unlimited shares? Hell the volume is not even 2 mill yet and all itlooks like is market makers flipping shares.I want to buy another 40,000 shares before the week is over to round off a block,today might be the best time but they still could shake it down to .035 or so.I'll be watchin closely,I pulled all my current buys and even the testers for now and hopefully will be able to get them all in one buy.
posted
check out level 2,theres very few shares down at these levels and the next step is well back into the .04's.Wonder of ARCA could be just consolidating before the run up.
posted
Quest, looking for some Level 2 101 lessons here and I know 80% on about how to read, but where can you get a sense of available shares (I son't think just the bid size tells one anything?) at each level? I see each MM at their price, but is it possible to calculate X number of shares between point A and point B? Thanks!
-------------------- I may be wrong, but I don't think so.... Posts: 837 | From: Madison, WI | Registered: Sep 2005
| IP: Logged |
UBBFriend: Email this page to someone!
Printer-friendly view of this topic
![[Smile]](smile.gif)
![[Big Grin]](biggrin.gif)
![[Frown]](frown.gif)
